Tonghua Golden-Horse Pharmaceutical Industry Co Ltd - Asset Resilience Ratio
Tonghua Golden-Horse Pharmaceutical Industry Co Ltd (000766) has an Asset Resilience Ratio of 0.02% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See 000766 current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2002–2025)
This chart shows how Tonghua Golden-Horse Pharmaceutical Industry Co Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Tonghua Golden-Horse Pharmaceutical Indu total assets.
Liquid Assets Composition Over Time
This chart breaks down Tonghua Golden-Horse Pharmaceutical Industry Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read how much debt does Tonghua Golden-Horse Pharmaceutical Indu carry for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥1.04 Million | 0.02% |
| Total Liquid Assets | CN¥1.04 Million | 0.02% |
Asset Resilience Insights
- Limited Liquidity: Tonghua Golden-Horse Pharmaceutical Industry Co Ltd maintains only 0.02% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Tonghua Golden-Horse Pharmaceutical Industry Co Ltd Industry Peers by Asset Resilience Ratio
Compare Tonghua Golden-Horse Pharmaceutical Industry Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Beijing Tongrentang Co Ltd
SHG:600085 |
Drug Manufacturers - Specialty & Generic | 0.50% |
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 5.50% |
|
Neuland Laboratories Limited
NSE:NEULANDLAB |
Drug Manufacturers - Specialty & Generic | 9.65% |
|
China Resources Double-Crane Pharmaceutical Co Ltd
SHG:600062 |
Drug Manufacturers - Specialty & Generic | 1.18% |
|
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267 |
Drug Manufacturers - Specialty & Generic | 0.01% |
Annual Asset Resilience Ratio for Tonghua Golden-Horse Pharmaceutical Industry Co Ltd (2002–2025)
The table below shows the annual Asset Resilience Ratio data for Tonghua Golden-Horse Pharmaceutical Industry Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.02% | CN¥1.07 Million ≈ $157.08K |
CN¥4.48 Billion ≈ $655.09 Million |
0.00pp |
| 2024-12-31 | 0.02% | CN¥1.09 Million ≈ $159.29K |
CN¥4.48 Billion ≈ $656.09 Million |
+0.00pp |
| 2023-12-31 | 0.02% | CN¥1.05 Million ≈ $153.44K |
CN¥4.52 Billion ≈ $661.31 Million |
+0.02pp |
| 2022-12-31 | 0.00% | CN¥128.39K ≈ $18.79K |
CN¥4.69 Billion ≈ $685.58 Million |
0.00pp |
| 2021-12-31 | 0.00% | CN¥180.33K ≈ $26.39K |
CN¥4.64 Billion ≈ $679.09 Million |
-1.86pp |
| 2020-12-31 | 1.86% | CN¥92.63 Million ≈ $13.55 Million |
CN¥4.98 Billion ≈ $728.92 Million |
+1.71pp |
| 2019-12-31 | 0.14% | CN¥6.80 Million ≈ $995.05K |
CN¥4.70 Billion ≈ $687.47 Million |
-0.15pp |
| 2018-12-31 | 0.30% | CN¥17.80 Million ≈ $2.60 Million |
CN¥5.96 Billion ≈ $871.88 Million |
-4.29pp |
| 2017-12-31 | 4.59% | CN¥262.80 Million ≈ $38.46 Million |
CN¥5.73 Billion ≈ $838.02 Million |
-0.34pp |
| 2016-12-31 | 4.93% | CN¥261.50 Million ≈ $38.27 Million |
CN¥5.30 Billion ≈ $776.07 Million |
+4.55pp |
| 2015-12-31 | 0.38% | CN¥15.90 Million ≈ $2.33 Million |
CN¥4.16 Billion ≈ $608.11 Million |
-- |
| 2014-12-31 | 0.00% | CN¥0.00 ≈ $0.00 |
CN¥1.29 Billion ≈ $188.12 Million |
-- |
| 2003-12-31 | 0.01% | CN¥80.00K ≈ $11.71K |
CN¥1.44 Billion ≈ $210.85 Million |
-0.01pp |
| 2002-12-31 | 0.01% | CN¥200.00K ≈ $29.27K |
CN¥1.53 Billion ≈ $224.00 Million |
-- |
About Tonghua Golden-Horse Pharmaceutical Industry Co Ltd
Tonghua Golden-Horse Pharmaceutical Industry Co,Ltd., together with its subsidiaries, engages in the research, development, manufacture, and sale of pharmaceutical products in China. The company provides anti-tumor drugs, gynecological medications, medication for rheumatic bone pain, urological medications, heat-clearing and detoxifying drugs, cardiovascular and cerebrovascular drugs, digestive m… Read more